These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33545251)

  • 1. Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer.
    Bohoudi O; Bruynzeel AME; Tetar S; Slotman BJ; Palacios MA; Lagerwaard FJ
    Radiother Oncol; 2021 Apr; 157():197-202. PubMed ID: 33545251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy.
    Willigenburg T; van der Velden JM; Zachiu C; Teunissen FR; Lagendijk JJW; Raaymakers BW; de Boer JCJ; van der Voort van Zyp JRN
    Radiother Oncol; 2022 Jun; 171():182-188. PubMed ID: 35489444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
    Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
    Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
    BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy.
    Nicosia L; Sicignano G; Rigo M; Figlia V; Cuccia F; De Simone A; Giaj-Levra N; Mazzola R; Naccarato S; Ricchetti F; Vitale C; Ruggieri R; Alongi F
    Acta Oncol; 2021 Feb; 60(2):215-221. PubMed ID: 32945701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.
    Nicosia L; Mazzola R; Rigo M; Giaj-Levra N; Pastorello E; Ricchetti F; Vitale C; Figlia V; Cuccia F; Ruggieri R; Alongi F
    Radiol Med; 2023 May; 128(5):612-618. PubMed ID: 37055672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity.
    Nicosia L; Ravelli P; Rigo M; Giaj-Levra N; Mazzola R; Pastorello E; Ricchetti F; Allegra AG; Ruggieri R; Alongi F
    Radiother Oncol; 2024 Jan; 190():110043. PubMed ID: 38056694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom.
    Bohoudi O; Lagerwaard FJ; Bruynzeel AME; Niebuhr NI; Johnen W; Senan S; Slotman BJ; Pfaffenberger A; Palacios MA
    Radiother Oncol; 2019 Dec; 141():200-207. PubMed ID: 31585817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis.
    Boldrini L; Romano A; Chiloiro G; Corradini S; De Luca V; Verusio V; D'Aviero A; Castelluccia A; Alitto AR; Catucci F; Grimaldi G; Trapp C; Hörner-Rieber J; Marchesano D; Frascino V; Mattiucci GC; Valentini V; Gentile P; Gambacorta MA
    Radiat Oncol; 2023 May; 18(1):84. PubMed ID: 37218005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results.
    Sandoval ML; Youssef I; Latifi K; Grass GD; Torres-Roca J; Rosenberg S; Yamoah K; Johnstone PA
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.
    Tetar SU; Bruynzeel AME; Oei SS; Senan S; Fraikin T; Slotman BJ; Moorselaar RJAV; Lagerwaard FJ
    Eur Urol Oncol; 2021 Aug; 4(4):628-634. PubMed ID: 32536573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT.
    Parikh NR; Lee PP; Raman SS; Cao M; Lamb J; Tyran M; Chin W; Gilchrist T; Agazaryan N; Mittauer K; Steinberg ML; Raldow AC
    JCO Oncol Pract; 2020 Nov; 16(11):e1378-e1385. PubMed ID: 32539652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
    Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
    Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.
    Parikh NR; Clark MA; Patel P; Kafka-Peterson K; Zaide L; Ma TM; Steinberg ML; Cao M; Raldow AC; Lamb J; Kishan AU
    Appl Radiat Oncol; 2021 Sep; 10(3):33-40. PubMed ID: 34671700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
    Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study comparing MR-guided radiation therapy (MRgRT) setup strategies for prostate treatment: repositioning vs. replanning.
    Kim JI; Park JM; Choi CH; An HJ; Kim YJ; Kim JH
    Radiat Oncol; 2019 Aug; 14(1):139. PubMed ID: 31387593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator.
    Yang J; Vedam S; Lee B; Castillo P; Sobremonte A; Hughes N; Mohammedsaid M; Wang J; Choi S
    Phys Imaging Radiat Oncol; 2021 Jan; 17():20-24. PubMed ID: 33898773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.
    Neylon J; Ma TM; Savjani R; Low DA; Steinberg ML; Lamb JM; Nickols NG; Kishan AU; Cao M
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1181-1191. PubMed ID: 38160916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.